|Bid||0.00 x 900|
|Ask||0.00 x 3200|
|Day's Range||117.60 - 120.71|
|52 Week Range||91.57 - 135.48|
|Beta (3Y Monthly)||1.31|
|PE Ratio (TTM)||19.91|
|Earnings Date||Feb 12, 2019 - Feb 18, 2019|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||140.89|
Is IQVIA Holdings, Inc. (NYSE:IQV) a good place to invest some of your money right now? We can gain invaluable insight to help us answer that question by studying the investment trends of top investors, who employ world-class Ivy League graduates, who are given immense resources and industry contacts to put their financial expertise to […]
IQVIA™ (IQV) today announced that it was awarded the 2018 Scrip Award for Best Contract Research Organization — Full-Service Provider. This marks the seventh time in the last 10 years that the company has received this award.
Orchestra BioMed, Inc. (“Orchestra BioMed” or the “Company”), a biomedical innovation company developing advanced therapeutic solutions to address major unmet medical needs, announced today that it has appointed Evan Ballantyne as its Chief Financial Officer (CFO). Mr. Ballantyne is an experienced financial and strategic leader in the biotech, medical device and information services industries with a proven track record of building and strengthening a company’s financial position during his career of more than 25 years. David Hochman, Chairman and Chief Executive Officer of Orchestra BioMed, commented, “Over the course of his career, Evan has played key roles in successfully leading companies in the full range of strategic options in financing including private equity and public offerings.
IQVIA intends to repurchase from the underwriter 2,000,000 shares (the “Repurchase”). IQVIA is not offering any stock in this transaction and will not receive any proceeds from the sale of the shares by the Selling Stockholders in the offering. IQVIA’s per-share purchase price for the repurchased shares will be the same as the per-share purchase price payable by the underwriter to the Selling Stockholders.
IQVIA Holdings Inc. (“IQVIA”) (IQV) announced today the launch of an underwritten, secondary public offering of 6,000,000 shares of its common stock by certain of its existing stockholders, including affiliates of TPG Global, LLC, CPP Investment Board Private Holdings, Inc. and investment funds associated with Bain Capital Investors, LLC (the “Selling Stockholders”), of which IQVIA intends to repurchase from the underwriter 2,000,000 shares (the “Repurchase”).
Innovative commercial engagement model for life sciences companies improves customer alignment
PRA Health's (PRAH) Center for Pediatric Clinical Development is likely to enhance pediatric clinical testing and design with the latest move.
Leading diabetes company plans deployment of IQVIA’s OCE technology solution to transform engagement with healthcare professionals and to improve the value of every client interact
IQVIA Holdings Inc (NYSE:IQV) saw significant share price volatility over the past couple of months on the NYSE, rising to the highs of $130.77 and falling to the lows of Read More...
IQVIA Holdings (IQV) continues to serve the life sciences industry with the help of advanced analytics, technology solutions and contract research services. However, high debt remains a major concern.
IQVIA (IQV) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Innovative Technology enables the pharmaceutical industry to transition to an orchestrated commercial model
IQVIA™ announced today the launch of Informed Consent Form Author, a SaaS eConsent tool for use in clinical trials. The online portal allows sponsors, sites, and contract research organizations to produce their own ICFs for delivery via eConsent or traditional paper.
IQVIA Holdings Inc. , announced today that Michael McDonnell, executive vice president and chief financial officer, will speak at the Credit Suisse 27th Annual Healthcare Conference in Scottsdale, AZ on Tuesday, November 13, 2018 at 1:40 p.m.
NEW YORK, Nov. 02, 2018 -- In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors,.
Iqvia Holdings jumped early Monday, then sank, after the medical-research company's third-quarter earnings topped expectations.
Revenue and earnings continued to march higher, but this key indicator of future demand should have bulls smiling from ear to ear.
IQVIA (IQV) delivered earnings and revenue surprises of 2.16% and 0.50%, respectively, for the quarter ended September 2018. Do the numbers hold clues to what lies ahead for the stock?